**Abstract**

Diabetes-related foot ulcers (DFU) are a serious public health issue, and one of the main causes of death for diabetics is foot ulcers. Matrix metalloproteinase are crucial to both the pathophysiology of wounds and the healing process. MMPs have not previously been a focus for the treatment of DFUs due to the difficulty in differentiating between active MMPs and the two catalytically inactive forms of MMPs and the clinical failure of broad-spectrum MMP inhibitors in cancer. Managing bacterial infections by focusing on this quorum sensing (QS)-regulated process different from other management strategies. Despite the fact that the medical community has a thorough grasp of diabetic foot ulcers, research is continuously being done to find the most effective treatment for this crippling condition that is also safe to provide. Diabetic foot ulcers are brought on by a variety of factors, so a combination of therapies rather than a single medication will be the most effective course of treatment. This book chapter discusses the identification of active MMP-9 as the molecular cause of the diabetic wounds' resistance to healing as well as the unique therapeutic strategy of inhibiting this proteinase and about role of inhibiting the quorum sensing (QS) system in the treatment of diabetic foot ulcer.

**Keywords:** diabetic foot ulcer, quorum sensing (QS) system and targeting matrix metallopeptidase-9 (MMP-9), antimicrobial peptide
